Combined androgen blockade: the case for bicalutamide.

Area of Science:

• Urology
• Medical Oncology
• Pharmacology

Background:

• Prostate cancer treatment often involves androgen deprivation therapy (castration).
• The androgen receptor can remain active despite castration due to various factors.
• Combination therapy with antiandrogens is a strategy to enhance treatment efficacy.

Purpose of the Study:

• To evaluate the survival benefit of combination therapy versus castration alone in prostate cancer.
• To determine the impact of different antiandrogen types on survival outcomes.

Main Methods:

• Meta-analysis of 26 randomized controlled trials comparing combination therapy to castration alone.
• Analysis of specific antiandrogens, including nonsteroidal (bicalutamide, nilutamide, flutamide) and steroidal agents.
• Review of historical trial data for bicalutamide 50 mg in androgen deprivation therapy.

Main Results:

• Combination therapy with nonsteroidal antiandrogens showed a significant overall survival benefit.
• Combination therapy with steroidal antiandrogens was associated with reduced survival compared to castration alone.
• Bicalutamide 50 mg demonstrated advantages including improved side-effect profile and potent inhibition of androgen receptor activation, potentially reducing prostate cancer mortality by 20%.

Conclusions:

• The choice of antiandrogen is critical in combination therapy for prostate cancer.
• Nonsteroidal antiandrogens, particularly bicalutamide 50 mg, offer a survival advantage in combination with castration.
• Bicalutamide 50 mg represents a favorable option for enhancing androgen deprivation therapy in prostate cancer management.